Published Paper Details:

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. The present investigation aimed at enhancing the oral bioavailability of Ambrisentan by improving its solubility and dissolution rate by preparing nanosuspensions. The nanosuspensions of Ambrisentan were prepared using emulsification solvent evaporation method. Various formulation as well as process parameters were optimized in order to achieve desirable size and saturation solubility. Characterization of the prepared nanosuspension was done with respect to particle size, zeta potential, saturation solubility, dissolution rate, morphology study (SEM), in-vitro dissolution study. The results indicated that increase in the stabilizer concentration of PEG 6000 shows 99.65% of drug release, so the formulations prepared by using PEG 6000 releases more drug release at the end of 30mins than the other stabilizers and follows first order kinetics. Nanosuspension seems to be a promising approach for bioavailability enhancement because of the simple method of its preparation and its universal applicability.